Clinical Trials Logo

Adult Onset Still's Disease clinical trials

View clinical trials related to Adult Onset Still's Disease.

Filter by:
  • None
  • Page 1

NCT ID: NCT05432960 Withdrawn - AOSD Clinical Trials

Efficacy and Safety Clinical Study of RPH-104 in Adult Onset Still's Disease (AOSD)

Start date: December 2023
Phase: Phase 3
Study type: Interventional

The primary objective of the study is to evaluate the efficacy of RPH-104 when administered at a dose of 160 mg on Day 0, Day 7, Day 21 and then once every 2 weeks (Q2W) subcutaneous (SC) in patients with Adult Onset Still's Disease (AOSD). Furthermore, the study is scheduled to investigate pharmacokinetic (PK) and pharmacodynamic (PD) parameters of RPH-104.

NCT ID: NCT04752371 Terminated - Clinical trials for Adult Onset Still's Disease

A Study to Evaluate Camoteskimab in Participants With Still's Disease

Start date: March 25, 2021
Phase: Phase 1
Study type: Interventional

The main purpose of the study is to evaluate the safety and tolerability of Camoteskimab in participants with Still's Disease.

NCT ID: NCT04717635 Active, not recruiting - Clinical trials for Adult Onset Still's Disease

Study of Efficacy and Safety of Canakinumab in Japanese Patients With AOSD

Start date: March 30, 2021
Phase: Phase 3
Study type: Interventional

This is a phase III study designed to provide efficacy and safety data for canakinumab administered for at least 48 weeks as subcutaneous (s.c.) injection every 4 weeks (q4wk) in Japanese patients with Adult Onset Still's Disease (AOSD). Interim analysis (IA) data at Week 28 and 48 from this study supports a registration submission of canakinumab in the indication of Adult still's disease (ASD) in Japan.

NCT ID: NCT02204293 Terminated - Clinical trials for Adult-Onset Still´s Disease

Canakinumab for Treatment of Adult-onset Still's Disease

CONSIDER
Start date: June 21, 2012
Phase: Phase 2
Study type: Interventional

The purpose of this trial is to investigate the efficacy of the treatment with canakinumab in participants with Adult-onset Still's Disease (AOSD) and active joint involvement.

NCT ID: NCT01033656 Completed - Clinical trials for Adult-Onset Still's Disease

Treatment of Refractory Adult-onset Still's Disease With Anakinra: a Randomized Study

NordicAOSD05
Start date: December 2005
Phase: Phase 2
Study type: Interventional

An open, randomized, parallel-group, comparative, multicentre study. Patients on corticosteroids (plus conventional therapy) will be randomized to receive anakinra (Kineret®), or one of the following: methotrexate, azathioprine, leflunomide, cyclosporin A or sulphasalazine. Patients enter the study if considered refractory to corticosteroids (prednisolone equivalent ≥10 mg/day) at the time of randomization. The randomized phase of the study will be followed by an open-label extension (OLE) phase, to follow-up drug survival, efficacy, tolerability and disease-related parameters of long-term treatment with anakinra or one of the study DMARDs or a combination of study drugs for additional 28 weeks.